Skip to main content
. 2022 Apr 29;13:876037. doi: 10.3389/fimmu.2022.876037

Figure 3.

Figure 3

Decay of the anti-SARS-CoV-2 antibodies after the second and third doses. The decay half-lives of neutralizing antibody (A), anti-RBD total antibody (B), and anti-Spike IgG (C) were estimated using a linear mixed effects model with censoring of titers above the positive threshold. Due to the small amount of data, the decay half-lives of anti-Spike IgM and anti-Spike IgA failed to fit the model.